$QURE
uniQure N.V.

2024 Q3 Form 10-Q Financial Statement

#000155837024010528 Filed on August 01, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $2.287M $11.13M
YoY Change 62.54% 359.37%
Cost Of Revenue $264.0K $234.0K
YoY Change -73.76% -82.69%
Gross Profit $2.023M $10.89M
YoY Change 404.49% 917.94%
Gross Profit Margin 88.46% 97.9%
Selling, General & Admin $11.58M $15.77M
YoY Change -35.96% -25.56%
% of Gross Profit 572.17% 144.76%
Research & Development $30.60M $33.66M
YoY Change -53.22% -26.52%
% of Gross Profit 1512.36% 308.99%
Depreciation & Amortization $2.986M $2.670M
YoY Change 14.32% 3.17%
% of Gross Profit 147.6% 24.51%
Operating Expenses $42.17M $49.42M
YoY Change -49.48% -25.28%
Operating Profit -$40.23M -$44.01M
YoY Change -50.87% -32.37%
Interest Expense -$4.181M -$11.34M
YoY Change -127.07% 250.36%
% of Operating Profit
Other Income/Expense, Net $1.915M $236.0K
YoY Change 739.91%
Pretax Income -$44.41M -$55.35M
YoY Change -50.46% -18.97%
Income Tax -$31.00K $948.0K
% Of Pretax Income
Net Earnings -$44.38M -$56.30M
YoY Change -50.45% -17.78%
Net Earnings / Revenue -1940.45% -506.01%
Basic Earnings Per Share -$0.91 -$1.16
Diluted Earnings Per Share -$0.91 -$1.16
COMMON SHARES
Basic Shares Outstanding 48.70M 48.55M
Diluted Shares Outstanding 48.72M 48.62M

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $435.2M $524.4M
YoY Change -33.95% -16.57%
Cash & Equivalents $251.6M $287.9M
Short-Term Investments $183.6M $236.6M
Other Short-Term Assets $23.58M $59.69M
YoY Change 35.36% 282.59%
Inventory $0.00 $0.00
Prepaid Expenses $19.29M $18.28M
Receivables $5.322M $7.850M
Other Receivables $0.00 $0.00
Total Short-Term Assets $464.1M $592.0M
YoY Change -33.09% -21.8%
LONG-TERM ASSETS
Property, Plant & Equipment $25.57M $26.19M
YoY Change -44.36% -67.25%
Goodwill $24.08M $23.11M
YoY Change -4.7% -11.16%
Intangibles
YoY Change
Long-Term Investments $28.26M
YoY Change
Other Assets $1.453M $5.278M
YoY Change -75.86% -73.77%
Total Long-Term Assets $181.7M $138.9M
YoY Change 2.1% -25.26%
TOTAL ASSETS
Total Short-Term Assets $464.1M $592.0M
Total Long-Term Assets $181.7M $138.9M
Total Assets $645.8M $730.8M
YoY Change -25.9% -22.48%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.441M $4.407M
YoY Change -2.56% -52.98%
Accrued Expenses $32.30M $26.49M
YoY Change 13.63% -15.41%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $71.27M $80.47M
YoY Change 3.89% 17.72%
LONG-TERM LIABILITIES
Long-Term Debt $51.11M $102.5M
YoY Change -49.61% -78.35%
Other Long-Term Liabilities $8.919M $3.054M
YoY Change 716.01% -92.5%
Total Long-Term Liabilities $518.7M $553.3M
YoY Change -2.89% 7.58%
TOTAL LIABILITIES
Total Short-Term Liabilities $71.27M $80.47M
Total Long-Term Liabilities $518.7M $553.3M
Total Liabilities $590.0M $633.7M
YoY Change -2.12% 7.51%
SHAREHOLDERS EQUITY
Retained Earnings -$1.057B -$1.012B
YoY Change 29.31% 39.13%
Common Stock $2.932M $2.930M
YoY Change 1.7% 1.84%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $55.82M $97.11M
YoY Change
Total Liabilities & Shareholders Equity $645.8M $730.8M
YoY Change -25.9% -22.48%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$44.38M -$56.30M
YoY Change -50.45% -17.78%
Depreciation, Depletion And Amortization $2.986M $2.670M
YoY Change 14.32% 3.17%
Cash From Operating Activities -$36.60M -$32.71M
YoY Change -194.05% -42.61%
INVESTING ACTIVITIES
Capital Expenditures $380.0K $604.0K
YoY Change -77.86% -43.76%
Acquisitions
YoY Change
Other Investing Activities $48.05M $78.54M
YoY Change -115.38% 67.45%
Cash From Investing Activities $47.67M $77.94M
YoY Change -115.18% 70.06%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -53.02M 50.00K
YoY Change 595.33% -99.99%
NET CHANGE
Cash From Operating Activities -36.60M -32.71M
Cash From Investing Activities 47.67M 77.94M
Cash From Financing Activities -53.02M 50.00K
Net Change In Cash -41.95M 45.28M
YoY Change -85.17% -87.39%
FREE CASH FLOW
Cash From Operating Activities -$36.60M -$32.71M
Capital Expenditures $380.0K $604.0K
Free Cash Flow -$36.98M -$33.32M
YoY Change -199.41% -42.63%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
47833830
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
48694569
dei Entity Central Index Key
EntityCentralIndexKey
0001590560
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
us-gaap Debt Instrument Variable Interest Rate Type Extensible Enumeration
DebtInstrumentVariableInterestRateTypeExtensibleEnumeration
http://fasb.org/us-gaap/2024#PrimeRateMember
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36294
dei Entity Registrant Name
EntityRegistrantName
uniQure N.V.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
P7
dei Entity Address Address Line1
EntityAddressAddressLine1
Paasheuvelweg 25
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
1105 BP
dei Entity Address City Or Town
EntityAddressCityOrTown
Amsterdam
dei Entity Address Country
EntityAddressCountry
NL
dei City Area Code
CityAreaCode
31
dei Local Phone Number
LocalPhoneNumber
20-240-6000
dei Security12b Title
Security12bTitle
Ordinary Shares, par value €0.05
dei Trading Symbol
TradingSymbol
QURE
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
48697619
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
287877000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
241360000
CY2024Q2 us-gaap Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss Current
DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent
236553000
CY2023Q4 us-gaap Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss Current
DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent
376532000
CY2024Q2 qure Accounts Receivable And Contract With Customer Asset Current
AccountsReceivableAndContractWithCustomerAssetCurrent
7850000
CY2023Q4 qure Accounts Receivable And Contract With Customer Asset Current
AccountsReceivableAndContractWithCustomerAssetCurrent
4193000
CY2023Q4 us-gaap Inventory Net
InventoryNet
12024000
CY2024Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
18278000
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
15089000
CY2024Q2 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
37964000
CY2024Q2 qure Other Current Assets And Receivables
OtherCurrentAssetsAndReceivables
3446000
CY2023Q4 qure Other Current Assets And Receivables
OtherCurrentAssetsAndReceivables
2655000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
591968000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
651853000
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
27900000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
55700000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
26186000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
46548000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
14925000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
28789000
CY2024Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
58659000
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
60481000
CY2024Q2 us-gaap Goodwill
Goodwill
23112000
CY2023Q4 us-gaap Goodwill
Goodwill
26379000
CY2024Q2 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
10718000
CY2023Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
12276000
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5278000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5363000
CY2024Q2 us-gaap Assets Noncurrent
AssetsNoncurrent
138878000
CY2023Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
179836000
CY2024Q2 us-gaap Assets
Assets
730846000
CY2023Q4 us-gaap Assets
Assets
831689000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
4407000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6586000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
26491000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
30534000
CY2024Q2 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
28060000
CY2023Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
28211000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3625000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
8344000
CY2024Q2 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
17885000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
80468000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
73675000
CY2024Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
102507000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
101749000
CY2024Q2 qure Liability From Royalty Financing Agreement Non Current
LiabilityFromRoyaltyFinancingAgreementNonCurrent
415940000
CY2023Q4 qure Liability From Royalty Financing Agreement Non Current
LiabilityFromRoyaltyFinancingAgreementNonCurrent
394241000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
12369000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
28316000
CY2024Q2 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
12078000
CY2023Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
14795000
CY2024Q2 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
7323000
CY2023Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
7543000
CY2024Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3054000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3700000
CY2024Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
553271000
CY2023Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
550344000
CY2024Q2 us-gaap Liabilities
Liabilities
633739000
CY2023Q4 us-gaap Liabilities
Liabilities
624019000
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.05
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.05
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
48694569
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
47833830
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
47833830
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
2930000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
2883000
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1162823000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1148749000
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-56320000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-53553000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1012326000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-890409000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
97107000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
207670000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
730846000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
831689000
CY2024Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
11126000
CY2023Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2422000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
19611000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
7747000
CY2024Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
234000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
384000
CY2024Q2 qure Cost Of Contract Manufacturing Revenues
CostOfContractManufacturingRevenues
7227000
CY2023Q2 qure Cost Of Contract Manufacturing Revenues
CostOfContractManufacturingRevenues
1352000
qure Cost Of Contract Manufacturing Revenues
CostOfContractManufacturingRevenues
16303000
qure Cost Of Contract Manufacturing Revenues
CostOfContractManufacturingRevenues
3787000
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
33655000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
46036000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
74347000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
106845000
CY2024Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
15767000
CY2023Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
21181000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
29704000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
39029000
CY2024Q2 us-gaap Costs And Expenses
CostsAndExpenses
56883000
CY2023Q2 us-gaap Costs And Expenses
CostsAndExpenses
68569000
us-gaap Costs And Expenses
CostsAndExpenses
120738000
us-gaap Costs And Expenses
CostsAndExpenses
149661000
CY2024Q2 us-gaap Other Income
OtherIncome
1983000
CY2023Q2 us-gaap Other Income
OtherIncome
1302000
us-gaap Other Income
OtherIncome
3359000
us-gaap Other Income
OtherIncome
3113000
CY2024Q2 us-gaap Other Expenses
OtherExpenses
236000
CY2023Q2 us-gaap Other Expenses
OtherExpenses
229000
us-gaap Other Expenses
OtherExpenses
470000
us-gaap Other Expenses
OtherExpenses
445000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-44010000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-65074000
us-gaap Operating Income Loss
OperatingIncomeLoss
-98238000
us-gaap Operating Income Loss
OperatingIncomeLoss
-139246000
CY2024Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
5805000
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
3229000
us-gaap Investment Income Interest
InvestmentIncomeInterest
12313000
us-gaap Investment Income Interest
InvestmentIncomeInterest
4898000
CY2024Q2 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
16157000
CY2023Q2 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
6840000
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
32254000
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
10402000
CY2024Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-989000
CY2023Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
374000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-2134000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-1995000
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-55351000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-68311000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-120313000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-146745000
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
948000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
163000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1604000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1044000
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-56299000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-68474000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-121917000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-145701000
CY2024Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-313000
CY2023Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
54000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-2837000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
5851000
CY2024Q2 us-gaap Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
-35000
us-gaap Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
-70000
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-56577000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-68420000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-124684000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-139850000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.16
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.16
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.44
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.44
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.51
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.51
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.06
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.06
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48622440
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
48622440
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47649520
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47649520
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48503475
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
48503475
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47543516
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47543516
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
412771000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-68474000
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
54000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
34000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8894000
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
41000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
353320000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
146754000
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-56299000
CY2024Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-278000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6880000
CY2024Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
50000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
97107000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
476009000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-145701000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
5851000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
121000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
16955000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
85000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
353320000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
207670000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-121917000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-2767000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
14071000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
50000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
97107000
us-gaap Profit Loss
ProfitLoss
-121917000
us-gaap Profit Loss
ProfitLoss
-145701000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
5299000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
5115000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
-6672000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
-1837000
us-gaap Share Based Compensation
ShareBasedCompensation
14071000
us-gaap Share Based Compensation
ShareBasedCompensation
16955000
qure Royalty Financing Agreement Interest Expense
RoyaltyFinancingAgreementInterestExpense
24840000
qure Royalty Financing Agreement Interest Expense
RoyaltyFinancingAgreementInterestExpense
3154000
qure Deferred Income Tax Expense Benefit With Adjustments
DeferredIncomeTaxExpenseBenefitWithAdjustments
1604000
qure Deferred Income Tax Expense Benefit With Adjustments
DeferredIncomeTaxExpenseBenefitWithAdjustments
-1044000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-1621000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
1212000
us-gaap Inventory Write Down
InventoryWriteDown
5839000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-2940000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-944000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-1681000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-1006000
qure Increase Decrease In Accounts Receivable And Contract Assets Prepaid Expenses And Other Current Assets And Receivables
IncreaseDecreaseInAccountsReceivableAndContractAssetsPrepaidExpensesAndOtherCurrentAssetsAndReceivables
7227000
qure Increase Decrease In Accounts Receivable And Contract Assets Prepaid Expenses And Other Current Assets And Receivables
IncreaseDecreaseInAccountsReceivableAndContractAssetsPrepaidExpensesAndOtherCurrentAssetsAndReceivables
-813000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2606000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3288000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1619000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1212000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-7898000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-11416000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-93286000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-135299000
us-gaap Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities
297806000
us-gaap Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities
52234000
us-gaap Payments To Acquire Held To Maturity Securities
PaymentsToAcquireHeldToMaturitySecurities
152936000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2948000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3416000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
141922000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
48818000
qure Proceeds From Royalty Financing Agreement
ProceedsFromRoyaltyFinancingAgreement
374350000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
4288000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
50000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
206000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
50000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
370268000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-2191000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1812000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
46495000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
285599000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
244544000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
231173000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
291039000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
516772000
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
287877000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
513598000
CY2024Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
3162000
CY2023Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
3174000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
291039000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
516772000
us-gaap Interest Paid Net
InterestPaidNet
9261000
us-gaap Interest Paid Net
InterestPaidNet
8882000
qure Increase Decrease In Accounts Payable And Accrued Liabilities Related To Non Current Assets
IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedToNonCurrentAssets
-458000
qure Increase Decrease In Accounts Payable And Accrued Liabilities Related To Non Current Assets
IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedToNonCurrentAssets
-651000
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1</b></span>General business information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">uniQure N.V. (the “Company”) was incorporated on January 9, 2012, as a private company with limited liability (<i style="font-style:italic;">besloten vennootschap met beperkte aansprakelijkheid</i>) under the laws of the Netherlands. The Company is a leader in the field of gene therapy and seeks to deliver to patients suffering from rare and other devastating diseases single treatments with potentially curative results. The Company’s business was founded in 1998 and was initially operated through its predecessor company, Amsterdam Molecular Therapeutics Holding N.V. (“AMT”). In 2012, AMT undertook a corporate reorganization, pursuant to which uniQure B.V. acquired the entire business and assets of AMT and completed a share-for-share exchange with the shareholders of AMT. Effective February 10, 2014, in connection with its initial public offering, the Company converted into a public company with limited liability (<i style="font-style:italic;">naamloze vennootschap</i>) and changed its legal name from uniQure B.V. to uniQure N.V.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 1pt 0pt 1pt;"><span style="margin-left:0pt;margin-right:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company is registered in the trade register of the Dutch Chamber of Commerce (<i style="font-style:italic;">Kamer van Koophandel</i>) in Amsterdam, the Netherlands under number 54385229. The Company’s headquarters are in Amsterdam, the Netherlands, and its registered office is located at Paasheuvelweg 25a, Amsterdam 1105 BP, the Netherlands and its telephone number is +31 20 240 6000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company’s ordinary shares are listed on the Nasdaq Global Select Market and trade under the symbol “QURE”.</p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">2.3</b></span><b style="font-weight:bold;">Use of estimates </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2024Q2 us-gaap Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss Current
DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent
236553000
CY2024Q2 qure Debt Securities Current Held To Maturity Accumulated Unrecognized Gain
DebtSecuritiesCurrentHeldToMaturityAccumulatedUnrecognizedGain
15000
CY2024Q2 us-gaap Debt Securities Current
DebtSecuritiesCurrent
236568000
CY2023Q4 us-gaap Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss Current
DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent
376532000
CY2023Q4 qure Debt Securities Current Held To Maturity Accumulated Unrecognized Gain
DebtSecuritiesCurrentHeldToMaturityAccumulatedUnrecognizedGain
139000
CY2023Q4 us-gaap Debt Securities Current
DebtSecuritiesCurrent
376671000
CY2024Q2 qure Investment Securities With Original Maturities Of Less Than90 Days When Purchased And Presented Within Cash And Cash Equivalents At Amortized Cost
InvestmentSecuritiesWithOriginalMaturitiesOfLessThan90DaysWhenPurchasedAndPresentedWithinCashAndCashEquivalentsAtAmortizedCost
26900000
CY2023Q4 qure Investment Securities With Original Maturities Of Less Than90 Days When Purchased And Presented Within Cash And Cash Equivalents At Amortized Cost
InvestmentSecuritiesWithOriginalMaturitiesOfLessThan90DaysWhenPurchasedAndPresentedWithinCashAndCashEquivalentsAtAmortizedCost
0
CY2023Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
7157000
CY2023Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
4109000
CY2023Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
758000
CY2023Q4 us-gaap Inventory Net
InventoryNet
12024000
CY2024Q2 us-gaap Inventory Write Down
InventoryWriteDown
4100000
us-gaap Inventory Write Down
InventoryWriteDown
5800000
us-gaap Inventory Write Down
InventoryWriteDown
0
CY2023Q2 us-gaap Inventory Write Down
InventoryWriteDown
0
CY2024Q2 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
5300000
CY2023Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
1600000
CY2024Q2 us-gaap Disposal Group Including Discontinued Operation Inventory Current
DisposalGroupIncludingDiscontinuedOperationInventoryCurrent
8000000.0
CY2024Q2 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
28100000
CY2023Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
28200000
CY2024Q2 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
40100000
CY2023Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
43000000.0
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
11019000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
16263000
CY2024Q2 qure Accruals For Services Provided By Vendors Not Yet Billed Current
AccrualsForServicesProvidedByVendorsNotYetBilledCurrent
13576000
CY2023Q4 qure Accruals For Services Provided By Vendors Not Yet Billed Current
AccrualsForServicesProvidedByVendorsNotYetBilledCurrent
12834000
CY2024Q2 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
1896000
CY2023Q4 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
1437000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
26491000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
30534000
CY2023Q4 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
1400000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
3300000
CY2024Q2 qure Share Based Compensation Arrangement By Share Based Payment Award Number Of Milestones Achieved
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMilestonesAchieved
2
CY2024Q2 qure Share Based Compensation Arrangement By Share Based Payment Award Number Of Milestones Achievement Considered Probable
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMilestonesAchievementConsideredProbable
2
CY2023Q4 qure Share Based Compensation Arrangement By Share Based Payment Award Number Of Milestones Achievement Considered Probable
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMilestonesAchievementConsideredProbable
2
CY2024Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.017
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.013
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.258
CY2023Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.002
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.007
CY2024Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8469508
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8030404
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8469508
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8030404
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false

Files In Submission

Name View Source Status
0001558370-24-010528-index-headers.html Edgar Link pending
0001558370-24-010528-index.html Edgar Link pending
0001558370-24-010528.txt Edgar Link pending
0001558370-24-010528-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
qure-20240630.xsd Edgar Link pending
qure-20240630x10q.htm Edgar Link pending
qure-20240630xex10d1.htm Edgar Link pending
qure-20240630xex10d2.htm Edgar Link pending
qure-20240630xex10d3.htm Edgar Link pending
qure-20240630xex10d4.htm Edgar Link pending
qure-20240630xex10d5.htm Edgar Link pending
qure-20240630xex31d1.htm Edgar Link pending
qure-20240630xex31d2.htm Edgar Link pending
qure-20240630xex32d1.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
qure-20240630_pre.xml Edgar Link unprocessable
qure-20240630x10q_htm.xml Edgar Link completed
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
qure-20240630_def.xml Edgar Link unprocessable
qure-20240630_cal.xml Edgar Link unprocessable
qure-20240630_lab.xml Edgar Link unprocessable